UNCITI-BROCETA GROUP
Edinburgh Cancer Research UK Centre, MRC Institute of Genetics & Molecular Medicine
University of Edinburgh
PRODUCT COMMERCIALIZATION
2016- Highly-selective mTOR Inhibitor eCF309 sold globally by Axon Medchem (Netherlands)
2010-14 SAFEctin Transfection Reagent and SAFEctin STEM licensed and produced by Deliverics Ltd (UK) and distributed by Albyn Medical (Spain), CoreSciences (South Korea) and Galen Lab (USA)
STARTUPS / SPIN-OUT COMPANIES
2015- THER-IP LTD (SC499733)
2010-16 DELIVERICS LIMITED (SC377672)
Provider of easy-to-use kits for delivering biomolecules into and onto cells
RESEARCH COLLABORATIONS WITH PHARMA
2017- Merck & Co. through a MRS Award
PATENT APPLICATIONS
PATENT APPLICATIONS
2016 PCT/GB2017/051379 Bioorthogonal prodrugs (University of Edinburgh). Priority date: 29/04/2016.
2015 PCT/GB2016/051057 Compounds (University of Edinburgh). Priority date: 21/05/2015. National filing (2009): US, Europe, Japan, China & Canada. GRANTED in US (US10294227B2) and Europe
2014 PCT/ES2015/070203 Purine Derivatives as DAPK1 Inhibitors (Universidad de Granada & University of Edinburgh). Priority date: 25/03/2014. GRANTED in Spain
2013 PCT/GB2014/051894 Bioorthogonal Methods and Prodrugs (University of Edinburgh). Priority date: 21/06/2013. National filing (2015): US and Europe.
2010 PCT/GB2011/000749 Cationic Lipids (University of Edinburgh). Priority date: 18/05/2010. National filing (2011): US (US8759104 B2, granted) and Europe (EP2571527; pending). —Licensed to DELIVERICS—
2007 PCT/GB2008/003527 Cationic Lipids (University of Edinburgh). Priority date: 19/10/2007. National filing (2009): US, Europe, India, Japan, Australia & Canada. —Licensed to DELIVERICS—